Philips' Respironics unit appoints new chief technology officer
This article was originally published in Clinica
John Pritchard has joined Philips' Respironics drug delivery unit as chief technology officer. In his new role, Dr Pritchard will be responsible for global R&D activities in respiratory drug delivery, focusing on next-generation adaptive aerosol delivery technology. These devices are designed to only deliver medication when the patient breathes in, increasing the chance of it reaching deep inside the lung and reducing the amount of escaped medication. Dr Pritchard has over 30 years of experience in the aerosol and respiratory field, most recently at AstraZeneca as head of respiratory project management. He has also worked for 3M Healthcare and GlaxoSmithKline. Dr Pritchard replaces John Denyer, who is retiring, having worked for Respironics since 1988.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.